$\require{mediawiki-texvc}$
  • 검색어에 아래의 연산자를 사용하시면 더 정확한 검색결과를 얻을 수 있습니다.
  • 검색연산자
검색연산자 기능 검색시 예
() 우선순위가 가장 높은 연산자 예1) (나노 (기계 | machine))
공백 두 개의 검색어(식)을 모두 포함하고 있는 문서 검색 예1) (나노 기계)
예2) 나노 장영실
| 두 개의 검색어(식) 중 하나 이상 포함하고 있는 문서 검색 예1) (줄기세포 | 면역)
예2) 줄기세포 | 장영실
! NOT 이후에 있는 검색어가 포함된 문서는 제외 예1) (황금 !백금)
예2) !image
* 검색어의 *란에 0개 이상의 임의의 문자가 포함된 문서 검색 예) semi*
"" 따옴표 내의 구문과 완전히 일치하는 문서만 검색 예) "Transform and Quantization"

과학기술 지식인프라 ScienceON

상세검색 다국어 입력
도움말도움말
쳇봇 이모티콘
안녕하세요!
ScienceON 챗봇입니다.
궁금한 것은 저에게 물어봐주세요.

논문 상세정보

MyON담기
내보내기

Niclosamide encapsulated polymeric nanocarriers for targeted cancer therapy

RSC advances v.9 no.46 , 2019년, pp.26572 - 26581  
Jain, Nishant Kumar (Department of Biosciences and Bioengineering ) ;  R. S., Prabhuraj ( Centre for Research in Nanotechnology and Science ) ;  Bavya, M. C. ( Department of Biosciences and Bioengineering ) ;  Prasad, Rajendra ( Department of Biosciences and Bioengineering ) ;  Bandyopadhyaya, Rajdip ( Department of Chemical Engineering ) ;  Naidu, V. G. M. ( Department of Pharmacology & Toxicology ) ;  Srivastava, Rohit ( Department of Biosciences and Bioengineering)
Abstract

Localized cancer rates are on an upsurge, severely affecting mankind across the globe. Timely diagnosis and adopting appropriate treatment strategies could improve the quality of life significantly reducing the mortality and morbidity rates. Recently, nanotherapeutics has precipitously shown increased efficacy for controlling abnormal tissue growth in certain sites in the body, among which ligand functionalized nanoparticles (NP) have caught much attention for improved survival statistics via active targeting. Our focus was to repurpose the antihelminthic drug, niclosamide (NIC), which could aid in inhibiting the abnormal growth of cells restricted to a specific region. The work here presents a one-pot synthesis of niclosamide encapsulated, hyaluronic acid functionalized core-shell nanocarriers [(NIC-PLGA NP)HA] for active targeting of localized cancer. The synthesized nanocarriers were found to possess spherical morphology with mean size of 150.8 ± 9 nm and zeta potential of −24.9 ± 7.21 mV. The encapsulation efficiency was found to be 79.19 ± 0.16% with a loading efficiency of 7.19 ± 0.01%. The nanohybrids exhibited extreme cytocompatibility upon testing with MDA-MB-231 and L929 cell lines. The rate of cancer cell elimination was approximately 85% with targeted cell imaging results being highly convincing. [(NIC-PLGA NP)HA] demonstrates increased cellular uptake leading to a hike in reactive oxygen species (ROS) generation, combating tumour cells aiding in the localized treatment of cancer and associated therapy..

  

참고문헌 (56)

  1. 1. J. Med. Hypotheses Ideas Wiwanitkit 7 3 2013 10.1016/j.jmhi.2012.10.002 
  2. 2. ACS Biomater. Sci. Eng. Ediriwickrema 1 64 2015 10.1021/ab500084g 
  3. 3. J. Am. Med. Assoc. Goodman 132 126 1946 10.1001/jama.1946.02870380008004 
  4. 4. Nature Elbashir 411 494 2001 10.1038/35078107 
  5. 5. Nature Minke 254 84 1975 10.1038/253600a0 
  6. 6. Eur. J. Cardiothorac. Surg. Rizzoli 2 18 1988 10.1016/1010-7940(88)90091-7 
  7. 7. Nat. Nanotechnol. Peer 2 751 2007 10.1038/nnano.2007.387 
  8. 8. Adv. Nat. Sci. Nanosci. Nanotechnol. Biswas 5 043001 2014 10.1088/2043-6262/5/4/043001 
  9. 9. Adv. Drug Deliv. Rev. Costa 138 105 2018 10.1016/j.addr.2018.09.004 
  10. 10. Int. J. Pharm. Kreuter 331 1 2007 10.1016/j.ijpharm.2006.10.021 
  11. 11. J. Mater. Chem. B Singh 2 8069 2014 10.1039/C4TB01083C 
  12. 12. Advanced nanomedicine and nanobiotechnology Wiwanitkit 2008 V.Wiwanitkit , Advanced nanomedicine and nanobiotechnology , 2008 
  13. 13. ACS Appl. Bio Mater. Prasad 2 3312 2019 10.1021/acsabm.9b00335 
  14. 14. Theranostics Opoku-Damoah 6 986 2016 10.7150/thno.14860 
  15. 15. Nat. Rev. Cancer Huang 10 215 2014 10.1038/nrc.2016.108.Cancer 
  16. 16. J. Nanomed. Nanotechnol. Anderson 7 e143 2016 10.4172/2157-7439.1000 
  17. 17. J. Controlled Release Barenholz 160 117 2012 10.1016/j.jconrel.2012.03.020 
  18. 18. Nanotheranostics Sneider 1 1 2017 10.7150/ntno.17109 
  19. 19. Polymers Makadia 3 1377 2011 10.3390/polym3031377.Poly 
  20. 20. J. Controlled Release Danhier 161 505 2012 10.1016/j.jconrel.2012.01.043 
  21. 21. Biomaterials Jain 21 2475 2000 10.1016/S0142-9612(00)00115-0 
  22. 22. Expert Rev. Mol. Med. Lu 9 325 2009 10.1586/erm.09.15.Current 
  23. 23. J. Pharm. Invest. Choi 42 155 2012 10.1007/s40005-012-0024-5 
  24. 24. J. Control. Release. Passerini 73 111 2001 10.1016/S0168-3659(01)00245-0 
  25. 25. J. Drug Targeting Mattheolabakis 23 605 2015 10.3109/1061186X.2015.1052072 
  26. 26. Int. J. Cancer Deed 71 251 1997 10.1002/(SICI)1097-0215(19970410)71:2<251::AID-IJC21>3.0.CO;2-J 
  27. 27. J. Leukocyte Biol. Bollyky 86 567 2009 10.1189/jlb.0109001 
  28. 28. J. Biol. Chem. Wolny 285 30170 2010 10.1074/jbc.M110.137562 
  29. 29. Drug Deliv. Huang 25 766 2018 10.1080/10717544.2018.1450910 
  30. 30. Polymers Kim 10 1133 2018 10.3390/polym10101133 
  31. 31. Nat. Med. Tao 20 1263 2014 10.1038/nm.3699 
  32. 32. Cancer Lett. Li 349 8 2014 10.1016/j.canlet.2014.04.003 
  33. 33. Cell Shuai 76 821 1994 10.1016/0092-8674(94)90357-3 
  34. 34. Cell Clevers 149 1192 2012 10.1016/j.cell.2012.05.012 
  35. 35. Cancer Cell Guertin 12 9 2007 10.1016/j.ccr.2007.05.008 
  36. 36. Curr. Opin. Genet. Dev. Naugler 18 19 2008 10.1016/j.gde.2008.01.020 
  37. 37. Cancer Res. Shih 67 1879 2007 10.1158/0008-5472.CAN-06-3958 
  38. 38. J. Chem. Educ. Ramalho 93 1446 2016 10.1021/acs.jchemed.5b00837 
  39. 39. Int. J. Clin. Exp. Med. Sun 8 19670 2015 
  40. 40. Daru, J. Pharm. Sci. Gajra 23 1 2015 10.1186/s40199-014-0087-0 
  41. 41. AAPS PharmSciTech Yadav 11 1456 2010 10.1208/s12249-010-9519-4 
  42. 42. LWT-Food Sci. Technol. Pereira 63 100 2015 10.1016/j.lwt.2015.03.062 
  43. 43. Mater. Sci. Eng. C Bavya 95 226 2018 10.1016/j.msec.2018.10.080 
  44. 44. Colloids Surf., B George 160 315 2017 10.1016/j.colsurfb.2017.09.030 
  45. 45. ACS Appl. Mater. Interfaces Liu 8 11969 2016 10.1021/acsami.6b01135 
  46. 46. RSC Adv. Bhushan 5 12078 2015 10.1039/C4RA15233F 
  47. 47. Eur. J. Pharm. Biopharm. Okassa 67 31 2007 10.1016/j.ejpb.2006.12.020 
  48. 48. Sens. Actuators B Chem. Shen 181 605 2013 10.1016/j.snb.2013.02.054 
  49. 49. Int. J. Pharm. Van Tonder 269 417 2004 10.1016/j.ijpharm.2003.09.035 
  50. 50. Clin. Exp. Metastasis Martinez-Zaguilan 14 176 1996 10.1007/BF00121214 
  51. 51. J. Biol. Chem. Xu 277 11368 2002 10.1074/jbc.M108347200 
  52. 52. Methods Mol. Biol. Shen 437 183 2008 10.1007/978-1-59745-210-6_10 
  53. 53. Mol. Pharm. Qhattal 8 1233 2011 10.1021/mp2000428 
  54. 54. Sci. Rep. Amorim 1 2018 10.1038/s41598-018-34445-0 
  55. 55. Mol. Asp. Med. Cadenas 25 17 2004 10.1016/j.mam.2004.02.005 
  56. 56. Apoptosis Simon 5 415 2000 10.1023/A:1009616228304 

원문보기

원문 PDF 다운로드

  • 원문 PDF 정보가 존재하지 않습니다.

원문 URL 링크

원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다. (원문복사서비스 안내 바로 가기)

이 논문과 함께 이용한 콘텐츠

DOI 인용 스타일

"" 핵심어 질의응답